PE20151494A1 - Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer - Google Patents
Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancerInfo
- Publication number
- PE20151494A1 PE20151494A1 PE2015000485A PE2015000485A PE20151494A1 PE 20151494 A1 PE20151494 A1 PE 20151494A1 PE 2015000485 A PE2015000485 A PE 2015000485A PE 2015000485 A PE2015000485 A PE 2015000485A PE 20151494 A1 PE20151494 A1 PE 20151494A1
- Authority
- PE
- Peru
- Prior art keywords
- cancer
- elaboration
- compounds
- treatment
- novel process
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229940124647 MEK inhibitor Drugs 0.000 abstract 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713104P | 2012-10-12 | 2012-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151494A1 true PE20151494A1 (es) | 2015-11-06 |
Family
ID=49474740
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000485A PE20151494A1 (es) | 2012-10-12 | 2013-10-14 | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
| PE2019002024A PE20191818A1 (es) | 2012-10-12 | 2013-10-14 | Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3ol |
| PE2019001563A PE20200387A1 (es) | 2012-10-12 | 2019-08-08 | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002024A PE20191818A1 (es) | 2012-10-12 | 2013-10-14 | Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3ol |
| PE2019001563A PE20200387A1 (es) | 2012-10-12 | 2019-08-08 | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9771347B2 (enExample) |
| EP (1) | EP2909188B1 (enExample) |
| JP (2) | JP6300042B2 (enExample) |
| KR (1) | KR102204520B1 (enExample) |
| CN (2) | CN104837826B (enExample) |
| AU (1) | AU2013328929B2 (enExample) |
| BR (1) | BR112015008113B1 (enExample) |
| CA (1) | CA2889466C (enExample) |
| CL (1) | CL2015000926A1 (enExample) |
| CR (2) | CR20200237A (enExample) |
| EA (1) | EA030613B1 (enExample) |
| ES (1) | ES2671502T3 (enExample) |
| GE (1) | GEP201706690B (enExample) |
| HK (1) | HK1213567A1 (enExample) |
| HR (1) | HRP20180670T1 (enExample) |
| IL (1) | IL238116B (enExample) |
| IN (1) | IN2015DN03928A (enExample) |
| MA (1) | MA38085B1 (enExample) |
| MX (2) | MX372708B (enExample) |
| MY (1) | MY186549A (enExample) |
| NZ (1) | NZ706723A (enExample) |
| PE (3) | PE20151494A1 (enExample) |
| PH (1) | PH12015500785A1 (enExample) |
| PL (1) | PL2909188T3 (enExample) |
| SA (1) | SA515360271B1 (enExample) |
| SG (1) | SG11201502795VA (enExample) |
| SI (1) | SI2909188T1 (enExample) |
| TR (1) | TR201807861T4 (enExample) |
| UA (1) | UA115455C2 (enExample) |
| WO (1) | WO2014059422A1 (enExample) |
| ZA (1) | ZA201502349B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA115455C2 (uk) | 2012-10-12 | 2017-11-10 | Екселіксіс, Інк. | Спосіб одержання сполук для застосування при лікуванні раку |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| PL3316867T3 (pl) | 2015-06-30 | 2021-10-11 | Genentech, Inc. | Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek |
| CN105330643B (zh) * | 2015-12-09 | 2017-12-05 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
| CN106045969B (zh) * | 2016-05-27 | 2019-04-12 | 湖南欧亚药业有限公司 | 一种卡比替尼的合成方法 |
| WO2018031865A1 (en) | 2016-08-12 | 2018-02-15 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor |
| KR20190061030A (ko) | 2016-09-29 | 2019-06-04 | 제넨테크, 인크. | Mek 억제제, pd-1 축 억제제 및 탁산을 사용한 조합 요법 |
| WO2020187674A1 (en) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate |
| US20240173329A1 (en) | 2021-03-09 | 2024-05-30 | Genentech, Inc. | Belvarafenib for use in treatment of brain cancers |
| KR20230165795A (ko) | 2021-04-06 | 2023-12-05 | 제넨테크, 인크. | 벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1563587A (en) * | 1924-09-20 | 1925-12-01 | Raney Murray | Method of preparing catalytic material |
| US1628190A (en) * | 1926-05-14 | 1927-05-10 | Raney Murray | Method of producing finely-divided nickel |
| US1915473A (en) * | 1930-12-31 | 1933-06-27 | Raney Murray | Method of preparing catalytic material |
| US4510139A (en) | 1984-01-06 | 1985-04-09 | Sterling Drug Inc. | Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity |
| US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
| US6048885A (en) | 1994-04-01 | 2000-04-11 | Shionogi & Co., Ltd. | Oxime derivative and bactericide containing the same as active ingredient |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| WO1998037881A1 (en) | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| KR20010014360A (ko) | 1997-07-01 | 2001-02-26 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 2-(4-브로모 또는 4-요오도 페닐아미노)벤조산 유도체 및ｍｅｋ 억제제로서의 그의 용도 |
| BR9810366A (pt) | 1997-07-01 | 2000-08-29 | Warner Lambert Co | Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mek |
| US6974878B2 (en) | 2001-03-21 | 2005-12-13 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
| CA2346684A1 (en) | 1998-12-15 | 2000-06-22 | Warner-Lambert Company | Use of a mek inhibitor for preventing transplant rejection |
| IL143236A0 (en) | 1998-12-16 | 2002-04-21 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
| EP1140291B1 (en) | 1998-12-22 | 2005-11-23 | Warner-Lambert Company Llc | Combination chemotherapy comprising a mitotic inhibitor and a mek inhibitor |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| WO2000040237A1 (en) | 1999-01-07 | 2000-07-13 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| JP2002534380A (ja) | 1999-01-07 | 2002-10-15 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による喘息の治療 |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| EA200100772A1 (ru) | 1999-01-13 | 2002-02-28 | Варнер-Ламберт Компани | Бензогетероциклы и их применение в качестве мек ингибиторов |
| EP1150950A2 (en) | 1999-01-13 | 2001-11-07 | Warner-Lambert Company | Anthranilic acid derivatives |
| PL348870A1 (en) | 1999-01-13 | 2002-06-17 | Warner Lambert Co | 1-heterocycle substituted diarylamines |
| BR9916885A (pt) | 1999-01-13 | 2001-11-20 | Warner Lambert Co | Derivados de benzeno-sulfonamida e seu uso comoinibidores da mek |
| KR20020012315A (ko) | 1999-07-16 | 2002-02-15 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법 |
| JP2003504399A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法 |
| HK1047895A1 (zh) | 1999-07-16 | 2003-03-14 | 沃尼尔‧朗伯公司 | 使用mek抑制剂治疗慢性疼痛的方法 |
| EP1202731A2 (en) | 1999-07-16 | 2002-05-08 | Warner-Lambert Company Llc | Method for treating chronic pain using mek inhibitors |
| BRPI0014076B8 (pt) | 1999-09-17 | 2021-05-25 | Millennium Pharm Inc | benzamidas e inibidores correlatos do fator xa |
| MXPA02008103A (es) | 2000-03-15 | 2002-11-29 | Warner Lambert Co | Diarilaminas sustituidas con 5-amida como inhibidores mek. |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| AP2001002217A0 (en) | 2000-07-19 | 2001-09-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids. |
| CZ2003477A3 (cs) * | 2000-08-25 | 2003-10-15 | Warner - Lambert Company Llc | Způsob přípravy N-aryl-anthranilových kyselin a jejich derivátů |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| NZ518726A (en) | 2001-05-09 | 2004-06-25 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US20040039208A1 (en) * | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
| DE10141266A1 (de) | 2001-08-21 | 2003-03-06 | Syntec Ges Fuer Chemie Und Tec | Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden |
| US7085492B2 (en) | 2001-08-27 | 2006-08-01 | Ibsen Photonics A/S | Wavelength division multiplexed device |
| IL160967A0 (en) | 2001-10-31 | 2004-08-31 | Pfizer Prod Inc | Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome |
| DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
| CA2473545A1 (en) | 2002-01-23 | 2003-07-31 | Warner-Lambert Company Llc | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| SI2130537T1 (sl) | 2002-03-13 | 2013-01-31 | Array Biopharma, Inc. | N3-alkilirani derivati benzimidazola kot inhibitorji mek |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| CA2478534A1 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
| AU2003238915B2 (en) | 2002-06-11 | 2008-02-21 | Merck & Co., Inc. | (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents |
| GB0214268D0 (en) | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
| AU2003248813A1 (en) | 2002-07-05 | 2004-01-23 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| US7521447B2 (en) | 2003-03-03 | 2009-04-21 | Array Biopharma Inc. | P38 inhibitors and methods of use thereof |
| TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
| JP2005162727A (ja) | 2003-03-18 | 2005-06-23 | Sankyo Co Ltd | スルファミド誘導体及びその医薬組成物 |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| AU2004249495A1 (en) | 2003-06-20 | 2004-12-29 | Ucb Pharma S.A. | Thienopyridone derivatives as kinase inhibitors |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| DE602004023207D1 (de) | 2003-07-24 | 2009-10-29 | Warner Lambert Co | Benzimidazol-derivate als mek-hemmer |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| TW200520745A (en) | 2003-09-19 | 2005-07-01 | Chugai Pharmaceutical Co Ltd | Novel 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors |
| DK1682138T3 (da) | 2003-11-19 | 2011-04-18 | Array Biopharma Inc | Heterocykliske inhibitorer af MEK |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| RU2361868C2 (ru) | 2003-12-08 | 2009-07-20 | Ф.Хоффманн-Ля Рош Аг | Новые производные тиазола |
| MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| CN101065358B (zh) * | 2004-10-20 | 2015-03-11 | 默克雪兰诺有限公司 | 3-芳基氨基吡啶衍生物 |
| WO2006061712A2 (en) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| BRPI0617165B1 (pt) * | 2005-10-07 | 2023-10-03 | Exelixis Inc | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos |
| ATE539752T1 (de) | 2006-08-16 | 2012-01-15 | Exelixis Inc | Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung |
| EP2101759B1 (en) * | 2006-12-14 | 2018-10-10 | Exelixis, Inc. | Methods of using mek inhibitors |
| UA115455C2 (uk) | 2012-10-12 | 2017-11-10 | Екселіксіс, Інк. | Спосіб одержання сполук для застосування при лікуванні раку |
| BR112016017648B1 (pt) | 2014-02-07 | 2021-01-19 | Sumitomo Chemical Company, Limited | método para produção de (r)-1,1,3-trimetil-4-aminoindano |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
-
2013
- 2013-10-14 UA UAA201504532A patent/UA115455C2/uk unknown
- 2013-10-14 GE GEAP201313824A patent/GEP201706690B/en unknown
- 2013-10-14 SG SG11201502795VA patent/SG11201502795VA/en unknown
- 2013-10-14 EP EP13780303.7A patent/EP2909188B1/en active Active
- 2013-10-14 CN CN201380064338.7A patent/CN104837826B/zh active Active
- 2013-10-14 MY MYPI2015000897A patent/MY186549A/en unknown
- 2013-10-14 SI SI201331045T patent/SI2909188T1/en unknown
- 2013-10-14 MX MX2015004660A patent/MX372708B/es active IP Right Grant
- 2013-10-14 BR BR112015008113-4A patent/BR112015008113B1/pt active IP Right Grant
- 2013-10-14 CR CR20200237A patent/CR20200237A/es unknown
- 2013-10-14 IN IN3928DEN2015 patent/IN2015DN03928A/en unknown
- 2013-10-14 WO PCT/US2013/064866 patent/WO2014059422A1/en not_active Ceased
- 2013-10-14 HR HRP20180670TT patent/HRP20180670T1/hr unknown
- 2013-10-14 CA CA2889466A patent/CA2889466C/en active Active
- 2013-10-14 EA EA201590700A patent/EA030613B1/ru not_active IP Right Cessation
- 2013-10-14 MA MA38085A patent/MA38085B1/fr unknown
- 2013-10-14 JP JP2015536988A patent/JP6300042B2/ja active Active
- 2013-10-14 TR TR2018/07861T patent/TR201807861T4/tr unknown
- 2013-10-14 PE PE2015000485A patent/PE20151494A1/es active IP Right Grant
- 2013-10-14 HK HK16101572.6A patent/HK1213567A1/zh unknown
- 2013-10-14 AU AU2013328929A patent/AU2013328929B2/en active Active
- 2013-10-14 KR KR1020157012066A patent/KR102204520B1/ko active Active
- 2013-10-14 NZ NZ706723A patent/NZ706723A/en unknown
- 2013-10-14 CN CN201810758236.XA patent/CN108948043B/zh active Active
- 2013-10-14 ES ES13780303.7T patent/ES2671502T3/es active Active
- 2013-10-14 PE PE2019002024A patent/PE20191818A1/es unknown
- 2013-10-14 PL PL13780303T patent/PL2909188T3/pl unknown
-
2015
- 2015-04-02 IL IL238116A patent/IL238116B/en active IP Right Grant
- 2015-04-08 PH PH12015500785A patent/PH12015500785A1/en unknown
- 2015-04-08 ZA ZA2015/02349A patent/ZA201502349B/en unknown
- 2015-04-10 MX MX2020005533A patent/MX2020005533A/es unknown
- 2015-04-12 SA SA515360271A patent/SA515360271B1/ar unknown
- 2015-04-13 CL CL2015000926A patent/CL2015000926A1/es unknown
- 2015-04-13 US US14/684,826 patent/US9771347B2/en active Active
- 2015-05-11 CR CR20150245A patent/CR20150245A/es unknown
-
2017
- 2017-08-25 US US15/686,333 patent/US10239858B2/en active Active
- 2017-12-06 JP JP2017234208A patent/JP2018052973A/ja not_active Withdrawn
-
2019
- 2019-02-08 US US16/271,215 patent/US10793541B2/en active Active
- 2019-08-08 PE PE2019001563A patent/PE20200387A1/es unknown
-
2020
- 2020-08-26 US US17/003,570 patent/US11414396B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20151494A1 (es) | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer | |
| NI201900019A (es) | Inhibidores de procesos metabólicos celulares | |
| ECSP14013284A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| MX2014001218A (es) | Tratamiento de cancer de mama. | |
| MX2016012097A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
| GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
| CR20130550A (es) | Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina | |
| MX387487B (es) | Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton. | |
| CR20140166A (es) | Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1 | |
| UY34132A (es) | Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab. | |
| MA40076A (fr) | Inhibiteurs de syk | |
| BR112015018249A2 (pt) | agente de tratamento, método de tratamento de uma chapa de aço, chapa de aço tratada e processo para a produção de uma chapa de aço tratada | |
| AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| BR112015005369A2 (pt) | inibidores de usp30 e métodos para sua utilização | |
| DOP2014000253A (es) | Inhibidores del nampt | |
| BR112013025777A2 (pt) | imidazopiridazinas como inibidores da quinase akt | |
| AR097882A1 (es) | Método para procesar la biomasa que contiene celulosa | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| EA201792096A3 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| GB201316955D0 (en) | Composition comprising a diindolymethane and a retinoid to treat a skin condition | |
| DOP2015000176A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| NI201400020A (es) | COMPOSICIONES Y MÉTODOS PARA TRATAR EL CÁNCER USANDO EL INHIBIDOR DE PI3Kbeta Y EL INHIBIDOR DE LA VÍA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
| UY33942A (es) | Derivados tópicos de piridil/pirazinil metilenoxi como inhibidores de la tirosina cinasa del bazo | |
| CL2012003201A1 (es) | Metodo para tratar una cdi en un mamifero que esta siendo sometido simultaneamente a una terapia con antibioticos para combatir una infeccion diferente, que comprende el uso de fidaxomicina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |